selank comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-30. Numbers and descriptions here follow the published literature rather than marketing material.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Derived from the seven-residue sequence |
| Molecular weight | About 751.9 g/mol | Average mass; the monoisotopic value is slightly lower |
| Residue count | Seven amino acids | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Parent compound | Tuftsin (Thr-Lys-Pro-Arg) | Selank extends tuftsin at the C-terminus |
| Compound class | Synthetic short peptide | Studied in a research setting; not a licensed drug in most markets |
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
amplification of the CCND1 gene / overexpression of cyclin D1; chromosomal translocation of the CCND1 gene; mutations in the degradation motif recognized by the CRL4-AMBRA1 E3 ubiquitin ligase; disruption of nuclear export and proteolysis of cyclin D1; induction of transcription by oncogenic Ras, Src, ErbB2 and STATs; Cyclin D1 overexpression is correlated with shorter cancer patient survival and increased metastasis. Amplification of the CCND1 gene is present in:
In 2015, she was a laureate of the L'Oréal-UNESCO For Women in Science Awards "for her groundbreaking work in macromolecular mass spectrometry and pioneering gas phase structural biology by probing the structure and reactivity of single proteins and protein complexes, including membrane proteins." In 2017, she was elected a Foreign Associate of the US National Academy of Sciences. In 2018, she won the Frank H. Field and Joe L. Franklin Award for Outstanding Achievement in Mass Spectrometry from the American Chemical Society. In 2019, she won the Novozymes Prize for "almost single-handedly founding a subfield of mass spectrometry proteomics". Also in 2019 she received the Royal Medal. In 2020, she was chosen as the recipient of the Othmer Gold Medal. In 2021, she received the 2022 Louis-Jeantet Prize for Medicine. and the 2022 European Chemistry Gold Medal by the European Chemical Society. Also in 2021, she became an International Honorary Member of the American Academy of Arts and Sciences. In 2022, she was awarded the Franklin Institute Award for Chemistry. In 2023, she was elected to the American Philosophical Society and was awarded the John B. Fenn Award for Distinguished Contribution to Mass Spectrometry. She was named one of the top ten "Innovators and Trailbalzers" on the 2023 Power List by the Analytical Scientist. In 2024, she received the EPO European Inventor Lifetime Achievement Award for her work in mass spectrometry that significantly advanced biochemical research and medical diagnostics.
=== CNBC documentary and lawsuit === In December 2010 lawyers from Cold Stone Creamery threatened a lawsuit over some of the contents of a then-upcoming documentary by CNBC. Behind the Counter: The Untold Story of Franchising reported on the failures and successes of franchising. After several edits the program was broadcast on CNBC on March 21, 2011. Brands such as Dunkin' Donuts and Five Guys were highlighted as successful franchise brands. Cold Stone Creamery's executives and corporate lawyers were interviewed. The lawsuit was discussed with former franchisees and the litigation threats with CNBC. An apparently successful Cold Stone franchise was also featured. Another expose was not aired due to threats of litigation and stores that were closed for years appeared on search engines for some unknown reason.
Sources: en.wikipedia.org
Aquarium granuloma (fish-tank granuloma, swimming-pool granuloma) Borderline lepromatous leprosy Borderline leprosy Borderline tuberculoid leprosy Buruli ulcer (Bairnsdale ulcer, Searl ulcer, Searle's ulcer) Erythema induratum (Bazin disease) Histoid leprosy Lepromatous leprosy Leprosy (Hansen's disease) Lichen scrofulosorum (tuberculosis cutis lichenoides) Lupus vulgaris (tuberculosis luposa) Miliary tuberculosis (disseminated tuberculosis, tuberculosis cutis acuta generalisata, tuberculosis cutis disseminata) Mycobacterium avium-intracellulare complex infection Mycobacterium haemophilum infection Mycobacterium kansasii infection Papulonecrotic tuberculid Primary inoculation tuberculosis (cutaneous primary complex, primary tuberculous complex, tuberculous chancre) Rapid-growing Mycobacterium infection Scrofuloderma (tuberculosis cutis colliquativa) Tuberculosis cutis orificialis (acute tuberculous ulcer, orificial tuberculosis) Tuberculosis verrucosa cutis (lupus verrucosus, prosector's wart, warty tuberculosis) Tuberculous cellulitis Tuberculous gumma (metastatic tuberculous abscess, metastatic tuberculous ulcer) Tuberculoid leprosy
He grew up speaking French and German, and studied English on a three-week course in Cambridge, learning Italian, and Spanish to help his career. He also has a working knowledge of Japanese. On 13 October 2020, Wenger's second book, My Life in Red & White: My Autobiography, was published by W&N, translated from French.
Criminal law is based on the Indian Penal Code originally intended for British India, and was at the time as a crown colony also adopted by the British colonial authorities in Singapore and remains the basis of the criminal code in the country with a few exceptions, amendments and repeals since it came into force. Trial by jury was abolished in 1970. Singapore is known for its strict laws and conservative stances on crime; both corporal punishment (by caning) and capital punishment (by hanging) are retained and commonly used as legal penalties.
Arizona Accelerator Mass Spectrometry Laboratory focuses on the study of cosmogenic isotopes, and in particular the study of radiocarbon, or Carbon-14. As a laboratory, part of its aim is to function as a research center, training center, and general community resource. Its stated mission is conducting original research in cosmogenic isotopes. The AMS laboratory was established in 1981 at the University of Arizona. This laboratory is used primarily to provide radiocarbon measurements. Hence, coverage in research areas is multidisciplinary. Coverage of dating objects includes general interest and scientific interest. For example, dating of the Dead Sea Scrolls was accomplished using this method.
Sources: en.wikipedia.org
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.
Tuftsin contains four residues, while selank carries an additional Pro-Gly-Pro segment at the carboxyl end. That extension is intended to reduce enzymatic cleavage. Comparative pharmacokinetic data in humans remain limited.
No single receptor target is widely accepted as the definitive mediator of the reported effects. Proposed contributors include GABAergic modulation, shifts in monoamine turnover, and altered neuropeptide degradation. The mechanism is treated in the literature as unresolved.
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.